Leukemia Clinical Trials in Denver

Showing 421-440 of 1,554 trials

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

NCT05275478

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG908, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 192 participants.

Locally Advanced Solid Tumor

Tango Therapeutics, Inc.192 participantsStarted Mar 2022

Los Angeles, California, United States • San Francisco, California, United States • Denver, Colorado, United States +17 more locations

COMPLETEDPhase 2< 1 mile

Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

NCT03694002

This randomized phase II trial studies how well carboplatin and paclitaxel with or without ramucirumab work in treating patients with thymic cancer that has spread to other places in the body, has come back, or cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as ramucirumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known if giving carboplatin and paclitaxel with or without ramucirumab will work better in treating patients with thymic cancer.

Locally Advanced Thymic CarcinomaMetastatic Thymic CarcinomaRecurrent Thymic Carcinoma+1 more

SWOG Cancer Research Network21 participantsStarted Mar 2019

Anchorage, Alaska, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +251 more locations

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

Leukemia Trials in Other Cities

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

ALTERRA Post-Approval Study

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Functional Lumen Opening With Self-Forming Magnetic Anastomosis

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Other Conditions in Denver